InsidersTradesSigma
PHARMANUTRA RISULTATI PRIMO SEMESTRE 2023 Stock: price and management transactions · Italy · Consob
Follow the PHARMANUTRA RISULTATI PRIMO SEMESTRE 2023 stock price and the full insider trade history of the company, a publicly traded company based in Italy. Shares are listed on IT IT, under the supervision of Consob. Operating in the Health Care sector, PHARMANUTRA RISULTATI PRIMO SEMESTRE 2023 has published 1 public disclosures. Market capitalisation: €861.8m. The latest transaction was reported on 11 September 2023 (Other). Among the most active insiders: Unknown. All data is accessible without an account.
1
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate PHARMANUTRA RISULTATI PRIMO SEMESTRE 2023 Strong Buy (bullish), based on 3 analysts. Average price target: €81.33.
Fundamental score
Ranked 8,053 of 26,212 companies
61.1
score / 100
Value37
Quality85
FCF yld1.9%
Earn yld2.3%
EV/EBITDA26.1x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 11 September 2023